ALLMedicine™ Oncology Treatment Center

Mar 16th, 2023 - Medulloblastoma is a rare tumor in adults. The objective of this nationwide, multicenter study was to evaluate the toxicity and efficacy of the Dutch treatment protocol for adult medulloblastoma patients. Adult medulloblastoma patients diagnosed b...

Mar 10th, 2023 - To characterize the supportive care (SC) needs and receipt of SC services among head and neck cancer (HNC) patients prior to oncologic treatment and to explore the influence of social determinants of health on these outcomes. Newly diagnosed HNC p...

Mar 3rd, 2023 - Combinations of drugs are becoming increasingly common in oncology treatment. In some cases, patients can benefit from the interaction between two drugs, although there is usually a higher risk of developing toxicity. Due to drug-drug interactions...

Mar 2nd, 2023 - Overall, this project has three main goals: first, to ascertain the feasibility of the approach and identify whether liquid biopsies can detect actionable mutations that can be utilized to generate precision oncology treatment recommendations. Sec...

Feb 1st, 2023 - It is estimated that between 50 and 80% of cancer patients in the United States (US) supplement their conventional medical treatment regimen with some form of complementary or alternative medicine (CAM) therapy or practice. A smaller percentage of...

Nov 1st, 2020 - The association between kidney disease and cancer is multifaceted and complex. Persons with chronic kidney disease (CKD) have an increased incidence of cancer, and both cancer and cancer treatments can cause impaired kidney function. Renal issues ...

Mar 2nd, 2023 - Overall, this project has three main goals: first, to ascertain the feasibility of the approach and identify whether liquid biopsies can detect actionable mutations that can be utilized to generate precision oncology treatment recommendations. Sec...

Feb 1st, 2023 - It is estimated that between 50 and 80% of cancer patients in the United States (US) supplement their conventional medical treatment regimen with some form of complementary or alternative medicine (CAM) therapy or practice. A smaller percentage of...

Jan 19th, 2023 - Novel data science and imaging-based methods to personalize care are being identified retrospectively and explored at many centers. Unfortunately, most of these methods require significant manual intervention to apply to any given patient situatio...

Dec 7th, 2022 - This study proposes to document the presence of clonal emergence and regression during radium-223 therapy for metastatic prostate cancer by serial ctDNA analysis of tumor-associated mutations, using the clinically-available Guardant 360 platform. ...

Nov 18th, 2022 - Trismus is defined as a limitation in the mouth/jaw-opening ability due to a reduced mandible mobility. Trismus can occur from benign jaw related conditions, often referred to as temporomandibular disorders (TMD). It can also result from local or ...

Mar 10th, 2022 - Kenneth J. Bloom, MD Chief Medical Of ficer Clarient, Inc The options for exploring tumor biology continue to multiply amid technological advances that are making molecular testing options a routine part of oncology treatment, particularly in br...

Mar 1st, 2022 - The oncology treatment landscape has evolved with the clinical development of precision-based therapeutic approaches and the growing availability of targeted agents.1,2 Over the last decade, targeted therapeutics have increasingly become an attrac...

Feb 24th, 2022 - Slow disease progression is often associated with low-grade follicular lymphoma. Despite the use of watch-and-wait approaches for the disease in early, low-grade stages, patients may eventually require treatment. Patients live with this disease fo...

Feb 16th, 2022 - After 7 years of explosive growth, the development of PD-1/PD-L1 immune checkpoint inhibitor (ICI) therapy underwent a course correction last year, with the withdrawal of a range of indications due to study results that failed to reach thresholds ...

Nov 17th, 2021 - American Oncology Network, LLC (AON), a high-growth medical oncology provider with a focus on supporting the long-term viability of oncology treatment in community-based settings, announced that John Misitis has joined as Vice President of Busines...